Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam
Status:
Completed
Trial end date:
2017-10-20
Target enrollment:
Participant gender:
Summary
This is a single center, non-randomized, open-label, fixed sequence study to investigate the
effect of multiple oral dosing of LEO 32731 (up-titrated), on CYP3A activity in healthy male
subjects using midazolam as a probe CYP3A substrate.
The study will be conducted in two seamless parts:
Part I - Maximal Tolerated Dose (MTD) Part II - Drug-Drug Interaction with midazolam